Study of QL1706 or QL1604 for limited-stage small cell lung cancer after chemoradiation
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests two new immunotherapy drugs (QL1706 or QL1604) to see if they can help prevent lung cancer from coming back after initial treatment with chemotherapy and radiation. It is for people with limited-stage small cell lung cancer who have completed standard chemoradiation and have not had their cancer grow.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have limited-stage small cell lung cancer (stages I–III) that hasn't spread to distant organs.
- You have completed 4 cycles of chemotherapy containing platinum and etoposide along with radiation therapy.
- After chemoradiation, your cancer either shrank, stayed the same, or disappeared (not worsened).
- You do not have active autoimmune or inflammatory conditions, and you do not have interstitial lung disease or active pneumonia.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called QL1706 combined with chemotherapy, given after standard chemoradiation, for people with limited-stage small cell lung cancer. The goal is to see if this combination helps keep the cancer from coming back.
This trial tests a new drug called QL1706 combined with chemotherapy for people with non-small cell lung cancer that has spread or come back after previous treatment with an immunotherapy drug (PD-1/PD-L1 inhibitor) plus chemotherapy. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a new treatment called QL1706 for people with cervical cancer that has come back or spread and has not responded to platinum-based chemotherapy. It aims to see if QL1706 can help shrink tumors and improve outcomes.
This trial studies whether a study drug called QL1706 added to standard platinum chemotherapy can lower the chance of lung cancer coming back after surgery. It targets people with stage II to IIIB non-small cell lung cancer who have had their tumor fully removed.
This trial tests two immunotherapy drugs (iparomlimab and tuvonralimab) before and after surgery for people with a certain type of lung cancer that can be removed. It aims to see if this treatment helps improve outcomes.
This trial tests a new immunotherapy drug, QL1706, given before surgery for esophageal squamous cell cancer. The goal is to see if it helps shrink tumors and improve outcomes for patients who are healthy enough for the treatment.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.